Financial Performance - Revenue decreased by approximately 34.9% to about RMB 277.5 million (FY2023: RMB 426.5 million) [3] - Profit before tax decreased by approximately 48.9% to about RMB 99.5 million (FY2023: RMB 194.6 million) [3] - Net profit for the year decreased by approximately 53.0% to about RMB 74.9 million (FY2023: RMB 159.3 million) [3] - Adjusted net profit (excluding non-recurring IPO expenses) decreased by approximately 49.5% to about RMB 87.0 million (FY2023: RMB 172.3 million) [3] - Earnings per share attributable to owners of the company was RMB 0.0999 (FY2023: RMB 0.2125) [3] - The company's total comprehensive income for the year was RMB 76.44 million (FY2023: RMB 162.84 million) [4] - For the fiscal year ending December 31, 2024, the company reported revenue of RMB 99,467,000, a decrease from RMB 194,621,000 in 2023, indicating a decline of approximately 48.9% [27] - The company's pre-tax profit for 2024 was RMB 99,467,000, significantly lower than RMB 194,621,000 in 2023, indicating a decrease of about 48.9% [27] - Basic earnings per share for 2024 were RMB 74,900,000, compared to RMB 159,344,000 in 2023, marking a decline of about 53% [27] Dividends - The board proposed a final dividend of RMB 0.0500 per ordinary share (equivalent to HKD 0.0537) for the year ending December 31, 2024 [3] - The company declared a dividend of RMB 550,000 per share for the fiscal year 2024 [9] - The board recommended a final dividend of RMB 0.050 per share for the year ended December 31, 2024, subject to approval at the upcoming annual general meeting [61] Assets and Liabilities - Total assets less current liabilities amounted to RMB 378.35 million (FY2023: RMB 413.50 million) [5] - Cash and cash equivalents decreased to RMB 235.82 million (FY2023: RMB 262.56 million) [5] - The company recognized contract liabilities of approximately RMB 308,000,000 as of December 31, 2024, compared to RMB 221,000,000 in 2023, showing an increase of about 39.4% [20] - As of December 31, 2024, the group's current assets net value was approximately RMB 358.6 million, compared to RMB 382.7 million as of December 31, 2023, with a current ratio of 10.6 times [46] - The group had no bank loans as of December 31, 2024, and completed a global offering of 250 million shares at HKD 0.80 per share, which is expected to support future business development [47] Operational Highlights - The company primarily operates in China, generating significant revenue from the sale of nutritional products, with external customer revenue being the main source [15] - The company's revenue for the fiscal year 2024 decreased by approximately RMB 149 million or 34.9%, primarily due to reduced demand in the maternal and infant nutrition market following a surge in 2023 and a temporary economic downturn in China during the first half of 2024 [33] - Online sales channels contributed approximately 80.5% of total revenue in fiscal year 2024, amounting to RMB 277.5 million, down from RMB 426.5 million in fiscal year 2023 [36] - The sales volume of DHA products in fiscal year 2024 was 1,276 thousand units, with an average selling price of RMB 209.0 per unit, compared to 1,918 thousand units and RMB 210.7 per unit in fiscal year 2023 [35] Expenses - The company incurred a loss of RMB 1,235,000 from foreign exchange in 2024, contrasting with a gain of RMB 1,163,000 in 2023 [22] - Employee costs decreased to RMB 12,077,000 in 2024 from RMB 16,600,000 in 2023, a reduction of approximately 27.5% [24] - Sales and distribution expenses for fiscal year 2024 were approximately RMB 90.6 million, a decrease from RMB 102.6 million in fiscal year 2023 [40] - The total tax expense for the year was RMB 24,567,000, down from RMB 35,277,000 in 2023, reflecting a reduction of approximately 30.5% [27] Corporate Governance - The company has adopted high standards of corporate governance practices, with the roles of Chairman and CEO currently held by the same individual, Mr. Wang Ping [65] - The audit committee was established on December 5, 2024, and consists of three independent non-executive directors, ensuring oversight of the audit process and risk management [69] - The company will continue to review and monitor its corporate governance practices to ensure compliance with the corporate governance code [66] - The company has confirmed compliance with the standard code for securities trading by directors since the listing date [68] Future Outlook - The company plans to increase marketing efforts in 2025 to enhance brand awareness and expand market coverage, particularly in underpenetrated regions of China [32] - The company has a strong confidence in the growth prospects of the nutrition industry in China, especially in the maternal and infant sector, driven by increasing health awareness and disposable income [32] Miscellaneous - The company's auditors confirmed that the financial statements for the year ending December 31, 2024, were prepared in accordance with applicable accounting standards [71] - As of December 31, 2024, the company's shares were not listed on the stock exchange, and no securities were purchased, sold, or redeemed during this period [72] - The annual performance announcement and annual report will be published on the company's website and the stock exchange website [73] - The board expresses gratitude to shareholders, management, employees, and business partners for their support and contributions [74] - The net proceeds from the share offering on January 10, 2025, are approximately HKD 124.0 million, with no changes planned for the intended use of proceeds as outlined in the prospectus [62] - The company will suspend share transfer registration from May 27, 2025, to May 30, 2025, to determine shareholder eligibility for the annual general meeting [63] - The company will also suspend share transfer registration from June 5, 2025, to June 6, 2025, to determine eligibility for the proposed final dividend [63]
纽曼思(02530) - 2024 - 年度业绩